RT Journal Article
T1 Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
A1 Recher, Christian
A1 Röllig, Christoph
A1 Berard, Emilie
A1 Bertoli, Sarah
A1 Dumas, Pierre-Yves
A1 Tavitian, Suzanne
A1 Kramer, Michael
A1 Serve, Hubert
A1 Bornhäuser, Martin
A1 Platzbecker, Uwe
A1 Müller-Tidow, Carsten
A1 Baldus, Claudia D
A1 Martinez-Cuadron, David
A1 Serrano, Josefina
A1 Martinez-Sanchez, Pilar
A1 Arboli, Eduardo Rodriguez
A1 Gil, Cristina
A1 Bergua, Juan
A1 Bernal, Teresa
A1 de la Fuente Burguera, Adolfo
A1 Delabesse, Eric
A1 Bidet, Audrey
A1 Pigneux, Arnaud
A1 Montesinos, Pau
K1 Leukemia, myeloid, acute
K1 Registries
K1 Treatment outcome
AB The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients ≥70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7-11.6) and 9.2 months (95% CI: 8.3-10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P < 0.0001). Treatment effect on overall survival was time-dependent. The Royston and Parmar model showed that patients treated with hypomethylating agents had a significantly lower risk of death before 1.5 months of follow-up; no significant difference between 1.5 and 4.0 months, whereas patients treated with intensive chemotherapy had a significantly better overall survival from four months after start of therapy. This study shows that intensive chemotherapy remains a valuable option associated with a better long-term survival in older AML patients.
PB Nature Publishing Group
YR 2021
FD 2021-09-13
LK http://hdl.handle.net/10668/22599
UL http://hdl.handle.net/10668/22599
LA en
NO Récher C, Röllig C, Bérard E, Bertoli S, Dumas PY, Tavitian S, et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2022 Apr;36(4):913-922
DS RISalud
RD Apr 19, 2025